FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPROVAL											
	OMB Number:	3235-0287										
l	Estimated average burden											

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## Filed nursuant to Section 16(a) of the Securities Eychange Act of 1934

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar BOREI	A	2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC ACAD										of Reporting cable) or (give title			Owner (specify					
(Last) 11085 TO	(F ORREYAN		3. Date of Earliest Transaction (Month/Day/Year) 11/26/2014									below)		below)		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
(Street) SAN DIEGO CA 92121						4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
(City)	(S		tive Securities Acquired, Disposed of, or Benefic																	
		ıan	ie i - N	on-Deri	vativ	e Sec	urit	ies Ac	quirea,	וט	sposea o	T, or Be	netici	ally	Owned					
Date					2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transacti Code (Ins 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			and 5) Securiti Benefic		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	′	Amount	(A) or (D)	Price		Transac (Instr. 3	ction(s)			(IIISU. 4)	
Common	Stock	2014	14			M		15,000	A	<b>\$1</b> :	1 15		5,000		D					
Common	Stock			11/26/2014 S <sup>(1)</sup> 15,000 D \$30.051 <sup>(2)</sup> 0 D																
		-	Table II								posed of, convertil				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deel Execution if any (Month/I		4. Transa Code ( 8)				6. Date E: Expiratio (Month/D	n Da		7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		D	. Price of Perivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	i lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal	sable	Expiration Date	Title	Amour or Number of Shares	ımber						
Stock Option (right to	\$11	11/26/2014			M			15,000	(3)		09/08/2015	Common Stock	15,00	0	\$0	0		D		

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2013.
- 2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$30.00 to \$30.18 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- 3. 50% of the shares subject to the stock option vested and became exercisable on September 9, 2006, and 50% of the shares subject to the stock option vested and became exercisable on September 9, 2007.

/s/ Glenn F. Baity, Attorney-in-Fact 11/26/2014

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.